This biweekly Vaccines Research video recap highlights regulatory momentum, late-stage clinical progress, early-phase innovation, and expanding global access across infectious disease and oncology pipelines. 🔬 Key highlights: 🫁 Vaxcyte completes Phase 3 enrollment for VAX-31 🦠 Clover reports additional RSV revaccination data for SCB-1019 🌎 GC Biopharma wins first Latin America approval for Barycela 🦟 Takeda’s Qdenga gets Indian expert committee nod 🧫 Delonix starts first-in-human Phase 1 for DX-104 💉 GC Biopharma wins Vietnam Phase 3 approval for two-dose BARYCELA 🎗️ Anixa moves breast cancer vaccine toward Phase 2 Chapters: 0:00 Introduction 0:07 Vaxcyte completes Phase 3 enrollment for VAX-31 0:30 Clover reports additional RSV revaccination data for SCB-1019 0:51 GC Biopharma wins first Latin America approval for Barycela 1:07 Takeda’s Qdenga gets Indian expert committee nod 1:21 Delonix starts first-in-human Phase 1 for DX-104 1:37 GC Biopharma wins Vietnam Phase 3 approval for two-dose BARYCELA 1:52 Anixa moves breast cancer vaccine toward Phase 2 2:10 How to reach us 📢 Stay Ahead in Vaccines Research! ✅ Like, share, and subscribe for future updates on Vaccines ✅ Visit www.lqventures.com for expert healthcare insights and consulting services ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Vaccines innovations and clinical research 🔔 Turn on notifications so you never miss an update! #Vaccines #FDA #ClinicalTrials #PharmaNews #Biotech #Immunology #DrugDevelopment #LucidQuest

GC Biopharma’s chickenpox vaccine, Barycela Inj. (Courtesy of GC Biopharma)GC Biopharma announced on Wednesday that its chickenpox vaccine, Barycela Inj., has received approval from the Drug Administration of Vietnam (DAV).Following the Korean approval of Barycela in 2020, GC GC Biopharma is acceler

GC Biopharma has received marketing authorization for its varicella vaccine, BARYCELA, in Guatemala, marking a crucial step in expanding access to vaccinations in Latin America.

GC Biopharma has submitted an IND for a Phase 3 trial of BARYCELA, a varicella vaccine, aiming for approval in Southeast Asia by 2027.

GC Biopharma's varicella vaccine BARYCELA has secured marketing authorization in Vietnam, a key step in its Southeast Asian expansion strategy.

- First regulatory clearance in Latin America marks a strategic milestone for regional market expansion - World's first antibiotic-free manufacturing process ensures superior safety profile YONGIN, South Korea, March 26, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of...

YONGIN, South Korea, Aug. 28, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Thailand Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial...

YONGIN, South Korea, July 17, 2025 /PRNewswire/ — GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of …